Osaka spinout Cuorips has added $14.7m to its coffers from investors including vehicles for the institution and Kyoto University, just three months after collecting $19.3m.

Cuorips, a Japan-based cell therapy developer spun out of Osaka University, has secured ¥1.6bn ($14.7m) from a consortium featuring respective vehicles for Osaka and Kyoto universities.
Handai Venture NVCC I and Kyodai Venture NVCC II, managed by Nippon Venture Capital on behalf of Osaka and Kyoto respectively, were joined in the round by regenerative medicine manufacturer CellSource and optics and medical engineering conglomerate Fujifilm.
VC firm Jafco’s SV6 and SV6-S funds filled out the round together with JIC…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
email
Linked in